From beta blockers to Ca2+ blockers in hypertension: a review.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003326:Coronary Circulation / Q000187:drug effects; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007022:Hypotension / Q000139:chemically induced; D008750:Methyldopa / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D014655:Vascular Resistance / Q000187:drug effects; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D008750:Methyldopa; D014700:Verapamil; D009543:Nifedipine